Arbutus Biopharma Corporation (NASDAQ:ABUS) Rating Lowered to Sell at ValuEngine

ValuEngine lowered shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) from a hold rating to a sell rating in a research report sent to investors on Tuesday, November 7th.

Other equities analysts have also issued reports about the company. JMP Securities restated an outperform rating and set a $13.00 price target (up from $12.00) on shares of Arbutus Biopharma Corporation in a research note on Wednesday, October 4th. Wedbush reaffirmed an outperform rating and set a $9.00 price objective on shares of Arbutus Biopharma Corporation in a report on Wednesday, September 20th. Leerink Swann reiterated a market perform rating and issued a $5.00 target price (up from $4.00) on shares of Arbutus Biopharma Corporation in a research note on Tuesday, November 7th. Zacks Investment Research raised shares of Arbutus Biopharma Corporation from a sell rating to a hold rating in a research note on Tuesday, November 7th. Finally, Chardan Capital reissued a buy rating on shares of Arbutus Biopharma Corporation in a research report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. Arbutus Biopharma Corporation has an average rating of Buy and an average price target of $13.00.

Arbutus Biopharma Corporation (NASDAQ:ABUS) opened at $5.75 on Tuesday. Arbutus Biopharma Corporation has a twelve month low of $2.35 and a twelve month high of $8.25. The company has a debt-to-equity ratio of 0.08, a quick ratio of 11.03 and a current ratio of 11.03.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/arbutus-biopharma-corporation-abus-downgraded-to-sell-at-valuengine/1763913.html.

In other news, insider Michael J. Sofia sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $8.00, for a total value of $80,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 10.00% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Arbutus Biopharma Corporation by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 2,035 shares in the last quarter. OxFORD Asset Management LLP grew its holdings in Arbutus Biopharma Corporation by 89.9% during the second quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock worth $300,000 after purchasing an additional 39,436 shares during the period. Renaissance Technologies LLC grew its holdings in Arbutus Biopharma Corporation by 785.1% during the first quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock worth $405,000 after purchasing an additional 110,499 shares during the period. Victory Capital Management Inc. acquired a new stake in Arbutus Biopharma Corporation during the second quarter worth approximately $478,000. Finally, Point72 Asset Management L.P. acquired a new stake in Arbutus Biopharma Corporation during the third quarter worth approximately $1,393,000. Institutional investors own 65.98% of the company’s stock.

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.